Leave no patient behind: how the FDA approval of Keytruda for specific biomarkers will put laboratory testing in the front line

The recent announcement that the FDA has granted approval to Merck’s Keytruda (pembrolizumab) “for a specific genetic feature (biomarker)” is leading us into a new era in which the integration of diagnostics and biomarker detection on the treatment pathway is not an option, but mandatory.
Existing Users Log In